MCID: ALK016
MIFTS: 45

Alk-Negative Anaplastic Large Cell Lymphoma

Categories: Cancer diseases, Blood diseases, Rare diseases, Immune diseases

Aliases & Classifications for Alk-Negative Anaplastic Large Cell Lymphoma

MalaCards integrated aliases for Alk-Negative Anaplastic Large Cell Lymphoma:

Name: Alk-Negative Anaplastic Large Cell Lymphoma 59
Anaplastic Large Cell Lymphoma, Alk Negative 73
Anaplastic Large Cell Lymphoma, Alk-Positive 73
Alk- Anaplastic Large Cell Lymphoma 59
Alk- Alcl 59

Characteristics:

Orphanet epidemiological data:

59
alk-negative anaplastic large cell lymphoma
Inheritance: Not applicable; Age of onset: Adult;

Classifications:



External Ids:

Orphanet 59 ORPHA300903
UMLS via Orphanet 74 C1332078
ICD10 via Orphanet 34 C84.7
ICD10 33 C84.7

Summaries for Alk-Negative Anaplastic Large Cell Lymphoma

MalaCards based summary : Alk-Negative Anaplastic Large Cell Lymphoma, also known as anaplastic large cell lymphoma, alk negative, is related to peripheral t-cell lymphoma and alk-positive anaplastic large cell lymphoma. An important gene associated with Alk-Negative Anaplastic Large Cell Lymphoma is ALK (ALK Receptor Tyrosine Kinase), and among its related pathways/superpathways are ERK Signaling and Endometrial cancer. The drugs Gemcitabine and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include t cells, breast and lymph node, and related phenotypes are endocrine/exocrine gland and growth/size/body region

Related Diseases for Alk-Negative Anaplastic Large Cell Lymphoma

Graphical network of the top 20 diseases related to Alk-Negative Anaplastic Large Cell Lymphoma:



Diseases related to Alk-Negative Anaplastic Large Cell Lymphoma

Symptoms & Phenotypes for Alk-Negative Anaplastic Large Cell Lymphoma

MGI Mouse Phenotypes related to Alk-Negative Anaplastic Large Cell Lymphoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.8 ADA ALK BAX BCL2 BCL2L1 DPP4
2 growth/size/body region MP:0005378 9.76 ADA ADARB1 ALK BAX BCL2 BCL2L1
3 neoplasm MP:0002006 9.43 BCL2 BCL2L1 CXCR3 TP63 ALK BAX
4 respiratory system MP:0005388 9.1 ADA ALK BAX CCR4 CXCR3 TP63

Drugs & Therapeutics for Alk-Negative Anaplastic Large Cell Lymphoma

Drugs for Alk-Negative Anaplastic Large Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 74)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gemcitabine Approved Phase 4,Phase 2 95058-81-4 60750
2
Etoposide Approved Phase 4,Phase 1,Phase 2 33419-42-0 36462
3
Cisplatin Approved Phase 4,Phase 2 15663-27-1 84093 441203 2767
4
Ifosfamide Approved Phase 4 3778-73-2 3690
5
Vincristine Approved, Investigational Phase 4,Phase 1,Phase 2 2068-78-2, 57-22-7 5978
6
Cyclophosphamide Approved, Investigational Phase 4,Phase 1,Phase 2 50-18-0, 6055-19-2 2907
7
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
8
Epirubicin Approved Phase 4 56420-45-2 41867
9
Prednisone Approved, Vet_approved Phase 4,Phase 1,Phase 2 53-03-2 5865
10
Doxorubicin Approved, Investigational Phase 4,Phase 1,Phase 2 23214-92-8 31703
11
Mechlorethamine Approved, Investigational Phase 4 51-75-2 4033
12
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
13
leucovorin Approved, Nutraceutical Phase 4 58-05-9 143 6006
14
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
15
Doxil Approved June 1999 Phase 4,Phase 1,Phase 2 31703
16
Pirarubicin Investigational Phase 4 72496-41-4
17 Dexamethasone acetate Phase 4 1177-87-3
18
Isophosphamide mustard Phase 4 0
19 Alkylating Agents Phase 4,Phase 1,Phase 2
20 glucocorticoids Phase 4,Phase 1,Phase 2
21 Topoisomerase Inhibitors Phase 4,Phase 1,Phase 2
22 Hormone Antagonists Phase 4,Phase 1,Phase 2
23 Hormones Phase 4,Phase 1,Phase 2
24 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 1,Phase 2
25 Anti-Bacterial Agents Phase 4,Phase 1,Phase 2
26 Antibiotics, Antitubercular Phase 4,Phase 1,Phase 2
27 Etoposide phosphate Phase 4,Phase 1,Phase 2
28 Immunosuppressive Agents Phase 4,Phase 1,Phase 2
29 Anti-Inflammatory Agents Phase 4,Phase 1,Phase 2
30 Antirheumatic Agents Phase 4,Phase 1,Phase 2
31 BB 1101 Phase 4
32 Antimitotic Agents Phase 4,Phase 1,Phase 2
33 Antineoplastic Agents, Alkylating Phase 4,Phase 1,Phase 2
34 Antineoplastic Agents, Hormonal Phase 4,Phase 1,Phase 2
35 Antineoplastic Agents, Phytogenic Phase 4,Phase 1,Phase 2
36 Dermatologic Agents Phase 4,Phase 1,Phase 2
37 Folic Acid Antagonists Phase 4
38 Nucleic Acid Synthesis Inhibitors Phase 4
39 Vitamin B Complex Phase 4
40 Antimetabolites Phase 4,Phase 2
41 Antimetabolites, Antineoplastic Phase 4,Phase 2
42 Folate Nutraceutical Phase 4
43 Vitamin B9 Nutraceutical Phase 4
44
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
45
Prednisolone Approved, Vet_approved Phase 1, Phase 2,Phase 2 50-24-8 5755
46
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177
47
Methylprednisolone Approved, Vet_approved Phase 1, Phase 2,Phase 2 83-43-2 6741
48
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030 46835353
49
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
50
Cortisone acetate Approved, Investigational Phase 1, Phase 2,Phase 2 1950-04-4, 50-04-4 5745

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Unknown status NCT02533700 Phase 4 CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
2 CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma Active, not recruiting NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
3 RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas Completed NCT01198665 Phase 1, Phase 2 RAD001 (Everolimus)
4 Combination Chemotherapy and Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma Recruiting NCT02561273 Phase 1, Phase 2 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Lenalidomide;Prednisone;Vincristine Sulfate
5 Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma Recruiting NCT03113500 Phase 2 Brentuximab Vedotin;Cyclophosphamide;Doxorubicin;Etoposide;Prednisone
6 Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Recruiting NCT03075553 Phase 2
7 CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study Active, not recruiting NCT01719835 Phase 2 Cyclophosphamide;Gemcitabine;Doxorubicin;Vincristine;Prednisolone;methylprednisolone;Cisplatin
8 Risk Stratification of Nodal PTCL Active, not recruiting NCT03040206

Search NIH Clinical Center for Alk-Negative Anaplastic Large Cell Lymphoma

Genetic Tests for Alk-Negative Anaplastic Large Cell Lymphoma

Anatomical Context for Alk-Negative Anaplastic Large Cell Lymphoma

MalaCards organs/tissues related to Alk-Negative Anaplastic Large Cell Lymphoma:

41
T Cells, Breast, Lymph Node, Bone, Bone Marrow

Publications for Alk-Negative Anaplastic Large Cell Lymphoma

Articles related to Alk-Negative Anaplastic Large Cell Lymphoma:

(show top 50) (show all 53)
# Title Authors Year
1
The Long Non-Coding RNA MIR503HG Enhances Proliferation of Human ALK-Negative Anaplastic Large-Cell Lymphoma. ( 29758012 )
2018
2
Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. ( 29026208 )
2018
3
FOXP3-positive T-cell lymphomas in non-HTLV1 carriers include ALK-negative anaplastic large cell lymphoma: expanding the Spectrum of T-cell lymphomas with regulatory phenotype. ( 29898383 )
2018
4
Prognostic factors of ALK-negative anaplastic large-cell lymphoma: a single-institution experience. ( 29359238 )
2018
5
ALK-Negative Anaplastic Large Cell Lymphoma Presenting as an Extranodal Soft-Tissue Mass With an Unusual Alveolar Growth Pattern: A Diagnostic Challenge. ( 28381153 )
2017
6
DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study. ( 28522440 )
2017
7
PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma. ( 28344319 )
2017
8
Indolent ALK-Negative Anaplastic Large Cell Lymphoma, DUSP22 Rearranged, with an Unusual Immunophenotype in an HIV Patient. ( 28042680 )
2017
9
Secondary CNS involvement of ALK-negative anaplastic large cell lymphoma. ( 28370436 )
2017
10
ALK-negative anaplastic large cell lymphoma with urinary bladder involvement diagnosed in urine cytology: A case report and literature review. ( 28139895 )
2017
11
Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin. ( 26809026 )
2016
12
Clinical and prognostic differences between ALK-negative anaplastic large cell lymphoma and peripheral T cell lymphoma, not otherwise specified: a single institution experience. ( 27209536 )
2016
13
ALK-negative anaplastic large cell lymphoma with CNS involvement needs more than just brentuximab vedotin. ( 27460479 )
2016
14
ALK-negative anaplastic large cell lymphoma with loss of CD30 expression during treatment with brentuximab vedotin. ( 27263791 )
2016
15
Morphologic Features of ALK-negative Anaplastic Large Cell Lymphomas With DUSP22 Rearrangements. ( 26379151 )
2016
16
ALK-negative anaplastic large-cell lymphoma. ( 26769771 )
2016
17
ALK-negative anaplastic large cell lymphoma is sensitive to bortezomib through Noxa upregulation and release of Bax from Bcl-2. ( 25975837 )
2015
18
Primary pancreatic ALK negative anaplastic large cell lymphoma. ( 25474521 )
2015
19
A case of ALK negative anaplastic large cell lymphoma with leukaemic manifestation, transformed from CD4 positive T-cell large granular lymphocytic leukaemia. ( 25474523 )
2015
20
Progress in the identification of subgroups in ALK-negative anaplastic large-cell lymphoma. ( 26223379 )
2015
21
Axillary Lymphadenopathy: An Outstanding Presentation for Breast Implant-Associated ALK-Negative Anaplastic Large Cell Lymphoma. ( 25829459 )
2015
22
PAX5-expressing ALK-negative anaplastic large cell lymphoma with extensive extranodal and nodal involvement. ( 26187868 )
2015
23
Flow cytometry of ALK-negative anaplastic large cell lymphoma of breast implant-associated effusion and capsular tissue. ( 24976005 )
2014
24
ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. ( 24894770 )
2014
25
Flow cytometry of ALK-negative anaplastic large cell lymphoma of breast implant-associated effusion and capsular tissue. ( 25044944 )
2014
26
Breast implant-associated ALK-negative anaplastic large cell lymphoma: a case report and discussion of possible pathogenesis. ( 23923082 )
2013
27
Intravascular ALK-negative anaplastic large cell lymphoma with localized cutaneous involvement and an indolent clinical course: toward recognition of a distinct clinicopathologic entity. ( 23480896 )
2013
28
Composite ALK-negative anaplastic large cell lymphoma and small lymphocytic lymphoma involving the right inguinal lymph node. ( 24169448 )
2013
29
Refractory Case of ALK-Negative Anaplastic Large-Cell Lymphoma with PAX-5 Expression and T-Cell Receptor-I^ Gene Rearrangement. ( 24369229 )
2013
30
Anaplastic large cell lymphoma, ALK-negative. ( 22789917 )
2013
31
ALK-negative anaplastic large cell lymphoma primarily involving the bronchus: a case report and literature review. ( 24427373 )
2013
32
Two cases of CD30+, anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma with oral manifestations. ( 22940020 )
2013
33
Systemic Capillary Leak Syndrome as an Initial Presentation of ALK-Negative Anaplastic Large Cell Lymphoma. ( 22953081 )
2012
34
Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma. ( 22740451 )
2012
35
High-risk ALK negative anaplastic large-cell lymphoma presenting with hypereosinophilic syndrome in a 2.5-year-old child. ( 23013405 )
2012
36
Extra copies of ALK gene locus is a recurrent genetic aberration and favorable prognostic factor in both ALK-positive and ALK-negative anaplastic large cell lymphomas. ( 22726922 )
2012
37
Leukemic presentation of ALK-negative anaplastic large cell lymphoma in a patient with myelodysplastic syndrome. ( 22246491 )
2012
38
Pathobiology of ALK-negative anaplastic large cell lymphoma. ( 22053281 )
2011
39
ALK-negative anaplastic large cell lymphoma mimicking a soft tissue sarcoma. ( 22090705 )
2011
40
Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. ( 21030553 )
2011
41
Rapid fatal pulmonary complications in a Chinese patient after bortezomib treatment for ALK-negative anaplastic large-cell lymphoma. ( 20371451 )
2010
42
Linkage of expression of chemokine receptors (CXCR3 and CCR4) and cytotoxic molecules in peripheral T cell lymphoma, not otherwise specified and ALK-negative anaplastic large cell lymphoma. ( 20217288 )
2010
43
Secondary ALK negative anaplastic large cell lymphoma in a patient with lymphomatoid papulosis of 40 years duration. ( 20644462 )
2010
44
ALK-negative anaplastic large cell lymphoma with extensive peripheral blood and bone marrow involvements manifested as "leukemic phase". ( 19695703 )
2010
45
ALK-negative anaplastic large cell lymphoma in leukemic phase with near-pentaploidy. ( 20846102 )
2010
46
Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas. ( 18275429 )
2008
47
Cutaneous presentation on the eyelid of primary, systemic, CD30+, anaplastic lymphoma kinase (ALK)-negative, anaplastic large-cell lymphoma (ALCL). ( 16796648 )
2006
48
CD26, together with cell surface adenosine deaminase, is selectively expressed on ALK-positive, but not on ALK-negative, anaplastic large cell lymphoma and Hodgkin's lymphoma. ( 17071493 )
2006
49
High-dose therapy and autologous stem cell transplant does not result in long-term disease-free survival in patients with recurrent chemotherapy-sensitive ALK-negative anaplastic large-cell lymphoma. ( 15004538 )
2004
50
ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified. ( 14636272 )
2003

Variations for Alk-Negative Anaplastic Large Cell Lymphoma

Expression for Alk-Negative Anaplastic Large Cell Lymphoma

Search GEO for disease gene expression data for Alk-Negative Anaplastic Large Cell Lymphoma.

Pathways for Alk-Negative Anaplastic Large Cell Lymphoma

Pathways related to Alk-Negative Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 30)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.66 ALK BAX BCL2 BCL2L1 CCR4 CXCR3
2
Show member pathways
12.68 BAX BCL2 BCL2L1 PMAIP1
3 12.66 ALK BAX BCL2 BCL2L1 PMAIP1
4
Show member pathways
12.62 BAX BCL2 BCL2L1 PMAIP1 TP63
5
Show member pathways
12.58 ALK BAX BCL2 BCL2L1
6
Show member pathways
12.22 BAX BCL2 BCL2L1 PMAIP1
7 12.12 BAX CCR4 PMAIP1
8
Show member pathways
12.08 BAX BCL2 BCL2L1
9 12.06 BAX BCL2 BCL2L1 PMAIP1
10 11.97 BAX BCL2 BCL2L1
11 11.85 BAX BCL2 PMAIP1 TP63
12 11.83 BAX BCL2 PMAIP1
13
Show member pathways
11.82 BAX BCL2 BCL2L1
14
Show member pathways
11.78 BAX PMAIP1 TP63
15 11.71 BAX BCL2 BCL2L1
16
Show member pathways
11.55 BAX BCL2 BCL2L1 PMAIP1
17
Show member pathways
11.45 BAX BCL2 BCL2L1 PMAIP1 TP63
18 11.42 BAX BCL2 BCL2L1 PMAIP1
19 11.39 BAX BCL2 BCL2L1
20 11.22 BAX BCL2L1 PMAIP1
21 11.14 BAX BCL2 BCL2L1
22 11.07 BAX BCL2
23 11.03 BCL2 BCL2L1
24
Show member pathways
11.01 BAX BCL2 BCL2L1 PMAIP1
25 10.95 BCL2 BCL2L1
26 10.94 BAX BCL2 BCL2L1
28 10.88 BAX BCL2
29 10.56 BAX BCL2
30
Show member pathways
10.27 BAX BCL2 PMAIP1 TP63

GO Terms for Alk-Negative Anaplastic Large Cell Lymphoma

Cellular components related to Alk-Negative Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mitochondrial membrane GO:0031966 9.43 BAX BCL2 BCL2L1
2 pore complex GO:0046930 9.16 BAX BCL2
3 Bcl-2 family protein complex GO:0097136 8.96 BAX BCL2L1
4 mitochondrial outer membrane GO:0005741 8.92 BAX BCL2 BCL2L1 PMAIP1

Biological processes related to Alk-Negative Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.99 ADA ALK BCL2 BCL2L1 TP63
2 apoptotic process GO:0006915 9.87 BAX BCL2 BCL2L1 CXCR3 DUSP22 PMAIP1
3 defense response to virus GO:0051607 9.85 ADARB1 BCL2 PMAIP1
4 cell proliferation GO:0008283 9.85 ALK BAX BCL2 BCL2L1 DUSP22 TP63
5 negative regulation of neuron apoptotic process GO:0043524 9.82 BAX BCL2 BCL2L1
6 regulation of cell cycle GO:0051726 9.82 ADARB1 BAX BCL2
7 male gonad development GO:0008584 9.8 BAX BCL2 BCL2L1
8 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.75 BAX BCL2 BCL2L1
9 ovarian follicle development GO:0001541 9.73 BAX BCL2 BCL2L1
10 regulation of apoptotic process GO:0042981 9.73 ALK BAX BCL2 BCL2L1 PMAIP1 TP63
11 response to radiation GO:0009314 9.72 BCL2 BCL2L1 CCR4
12 germ cell development GO:0007281 9.71 BAX BCL2L1
13 cellular response to glucose starvation GO:0042149 9.71 BCL2 PMAIP1
14 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.71 BCL2 BCL2L1
15 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.71 BAX BCL2 BCL2L1
16 reactive oxygen species metabolic process GO:0072593 9.7 BCL2 PMAIP1
17 intrinsic apoptotic signaling pathway by p53 class mediator GO:0072332 9.7 BAX PMAIP1
18 extrinsic apoptotic signaling pathway via death domain receptors GO:0008625 9.7 BAX BCL2
19 intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress GO:0070059 9.7 BAX BCL2
20 intrinsic apoptotic signaling pathway GO:0097193 9.69 BAX PMAIP1
21 behavioral fear response GO:0001662 9.69 BCL2 DPP4
22 cell aging GO:0007569 9.69 BCL2 TP63
23 positive regulation of release of cytochrome c from mitochondria GO:0090200 9.68 BAX PMAIP1
24 T cell homeostasis GO:0043029 9.68 BCL2 PMAIP1
25 homeostasis of number of cells within a tissue GO:0048873 9.68 BAX BCL2
26 hair follicle morphogenesis GO:0031069 9.67 BCL2 TP63
27 regulation of neuron apoptotic process GO:0043523 9.67 BAX TP63
28 negative regulation of intrinsic apoptotic signaling pathway GO:2001243 9.67 BCL2 BCL2L1
29 positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway GO:1900740 9.67 BCL2 PMAIP1 TP63
30 negative regulation of apoptotic signaling pathway GO:2001234 9.66 BAX BCL2
31 B cell homeostasis GO:0001782 9.66 BAX BCL2
32 homeostasis of number of cells GO:0048872 9.65 BAX CCR4
33 mitochondrion morphogenesis GO:0070584 9.65 BAX BCL2L1
34 response to gamma radiation GO:0010332 9.65 BAX BCL2 TP63
35 positive regulation of protein oligomerization GO:0032461 9.64 BAX PMAIP1
36 endoplasmic reticulum calcium ion homeostasis GO:0032469 9.63 BAX BCL2
37 growth GO:0040007 9.63 BCL2 BCL2L1
38 regulation of mitochondrial membrane potential GO:0051881 9.63 BAX BCL2 BCL2L1
39 regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043281 9.62 BAX TP63
40 regulation of protein heterodimerization activity GO:0043497 9.61 BAX BCL2
41 regulation of protein homodimerization activity GO:0043496 9.61 BAX BCL2
42 apoptotic mitochondrial changes GO:0008637 9.61 BAX BCL2 BCL2L1
43 protein insertion into mitochondrial membrane involved in apoptotic signaling pathway GO:0001844 9.6 BAX PMAIP1
44 leukocyte homeostasis GO:0001776 9.58 BAX BCL2
45 regulation of mitochondrial membrane permeability GO:0046902 9.58 BCL2 BCL2L1 PMAIP1
46 regulation of cell-cell adhesion mediated by integrin GO:0033632 9.57 ADA DPP4
47 regulation of nitrogen utilization GO:0006808 9.52 BAX BCL2
48 positive regulation of developmental pigmentation GO:0048087 9.51 BAX BCL2
49 neuron apoptotic process GO:0051402 9.46 BAX BCL2 BCL2L1 TP63
50 positive regulation of intrinsic apoptotic signaling pathway GO:2001244 9.26 BAX BCL2 BCL2L1 PMAIP1

Molecular functions related to Alk-Negative Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.43 ALK BAX BCL2 BCL2L1 DPP4 TP63
2 channel activity GO:0015267 9.32 BAX BCL2
3 chemokine receptor activity GO:0004950 9.26 CCR4 CXCR3
4 adenosine deaminase activity GO:0004000 9.16 ADA ADARB1
5 BH3 domain binding GO:0051434 8.8 BAX BCL2 BCL2L1

Sources for Alk-Negative Anaplastic Large Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....